MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient has been dosed in its Phase 1b/2 study (CELC-G-201) evaluating gedatolisib in combination with Nubeqa® (darolutamide), an approved androgen receptor inhibitor, for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC).

明尼阿波利斯，2024年2月22日（环球通讯社）--Celcuity Inc.（纳斯达克：CELC），一家开发肿瘤靶向治疗的临床阶段生物技术公司，今天宣布，第一名患者已在其1b/2期研究（CELC-G-201）中服用吉达托利西与Nubeqa®（达鲁酰胺）（一种经批准的雄激素受体抑制剂）联合使用，用于治疗转移性去势抵抗性前列腺癌（mCRPC）患者。

Gedatolisib, the company’s lead therapeutic candidate, is a potent, reversible dual inhibitor that selectively targets all Class 1 PI3K isoforms and mTORC1/2. “We are excited to begin enrolling patients in our 201 trial and advancing towards our ultimate goal of providing a transformative therapeutic option for patients with prostate cancer,” said Igor Gorbatchevsky, M.D.

该公司的主要治疗候选药物Gedatolisib是一种有效的可逆双重抑制剂，可选择性靶向所有1类PI3K亚型和mTORC1/2。医学博士Igor Gorbatchevsky说：“我们很高兴开始在201试验中招募患者，并朝着为前列腺癌患者提供变革性治疗选择的最终目标迈进。”。

Chief Medical Officer of Celcuity. “A significant unmet need remains for patients with metastatic castration resistant prostate cancer who have become resistant to a next generation androgen receptor inhibitor.” “Evaluating a PAM inhibitor, such as gedatolisib, in combination with a next generation androgen receptor, has strong scientific rationale and is an important priority for mCRPC research,” said Karim Fizazi, M.D., Ph.D., Professor of Medicine at Institute Gustave Roussy and GETUG President, and one of the primary principal investigators in the study.

Celcuity首席医疗官。“转移性去势抵抗性前列腺癌患者对下一代雄激素受体抑制剂产生耐药性的需求仍然没有得到满足。”“评估PAM抑制剂，如gedatolisib，与下一代雄激素受体联合使用，具有很强的科学依据，是mCRPC研究的重要优先事项，”医学博士Karim Fizazi说。，博士，古斯塔夫·鲁西研究所医学教授和格图格校长，也是该研究的主要主要研究者之一。

“As it stands, there are limited options for patients with mCRPC whose disease progressed on or after treatment with an androgen receptor inhibitor. Gedatolisib’s differentiated mechanism of action, and comprehensive blockade of the PAM pathway, may provide an additional treatment option for these patients.” In August 2023, Celcuity announced that it had entered into a clinical trial collaboration and su.

“目前，对于在雄激素受体抑制剂治疗时或治疗后疾病进展的mCRPC患者，选择有限。吉达托利西的分化作用机制和PAM途径的全面阻断可能为这些患者提供额外的治疗选择。”2023年8月，Celcuity宣布已与su进行临床试验合作。